*** CHEMICAL IDENTIFICATION ***
RTECS NUMBER : NJ5758500
CHEMICAL NAME : Imidazo(1,2-a)pyridine, 2-(p-(methylsulfonyl)phenyl)-
CAS REGISTRY NUMBER : 1222-57-7
BEILSTEIN REFERENCE NO. : 0752451
REFERENCE : 5-23-12-00328 (Beilstein Handbook Reference)
LAST UPDATED : 199712
DATA ITEMS CITED : 4
MOLECULAR FORMULA : C14-H12-N2-O2-S
MOLECULAR WEIGHT : 272.34
WISWESSER LINE NOTATION : T56 AN DNJ CR DSW1
COMPOUND DESCRIPTOR : Drug
SYNONYMS/TRADE NAMES :
* Imidazo(1,2-a)pyridine, 2-(4-(methylsulfonyl)phenyl)-
* 2-(4-(Methylsulfonyl)phenyl)imidazo(1,2-a)pyridine
* Solimidin
* Zolimidin
* Zolimidine
* Zoliridine
*** HEALTH HAZARD DATA ***
** ACUTE TOXICITY DATA **
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 3710 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
USXXAM United States Patent Document. (U.S. Patent Office, Box 9,
Washington, DC 20231) Volume(issue)/page/year: #3318880
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 950 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag,
Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951-
Volume(issue)/page/year: 33,1655,1983
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 4400 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
FMXXAJ French Medicament Patent Document. (U.S. Patent and Trademark
Office, Foreign Patents, Washington, DC 20231) Discontinued.
Volume(issue)/page/year: #8177M
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 765 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
FMXXAJ French Medicament Patent Document. (U.S. Patent and Trademark
Office, Foreign Patents, Washington, DC 20231) Discontinued.
Volume(issue)/page/year: #8177M
*** END OF RECORD ***